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Abstract
Background: Bone-resorbing osteoclasts are multinucleated cells that are formed via fusion of
their hematopoietic stem cells. Many of the details of osteoclast formation, activation and motility
remain unsolved. Therefore, there is an interest among bone biologists to transfect the terminally
differentiated osteoclasts and follow their responses to the transgenes in vitro. Severe difficulties in
transfecting the large, adherent osteoclasts have been encountered, however, making the use of
modern cell biology tools in osteoclast research challenging. Transfection of mature osteoclasts by
non-viral gene transfer systems has not been reported.
Results: We have systematically screened the usefulness of several commercial DNA transfection
systems in human osteoclasts and their mononuclear precursor cell cultures, and compared
transfection efficacy to adenoviral DNA transfection. None of the liposome-based or endosome
disruption-inducing systems could induce EGFP-actin expression in terminally differentiated
osteoclasts. Instead, a massive cell death by apoptosis was found with all concentrations and
liposome/DNA-ratios tested. Best transfection efficiencies were obtained by adenoviral gene
delivery. Marginal DNA transfection was obtained by just adding the DNA to the cell culture
medium. When bone marrow-derived CD34-positive precursor cells were transfected, some GFP-
expression was found at the latest 24 h after transfection. Large numbers of apoptotic cells were
found and those cells that remained alive, failed to form osteoclasts when cultured in the presence
of RANKL and M-CSF, key regulators of osteoclast formation. In comparison, adenoviral gene
delivery resulted in the transfection of CD34-positive cells that remained GFP-positive for up to 5
days and allowed osteoclast formation.
Conclusion: Osteoclasts and their precursors are sensitive to liposomal transfection systems,
which induce osteoclast apoptosis. Gene transfer to mononuclear osteoclast precursors or
differentiated osteoclasts was not possible with any of the commercial transfection systems tested.
Osteoclasts are non-dividing, adherent cells that are difficult to grow as confluent cultures, which
may explain problems with transfection reagents. Large numbers of αvβ3 integrin on the osteoclast
surface allows adenovirus endocytosis and infection proceeds in dividing and non-dividing cells
efficiently. Viral gene delivery is therefore currently the method of choice for osteoclast
transfection.
Published: 29 August 2005
Journal of Negative Results in BioMedicine 2005, 4:5 doi:10.1186/1477-5751-4-
5
Received: 18 January 2005
Accepted: 29 August 2005
This article is available from: http://www.jnrbm.com/content/4/1/5
© 2005 Laitala-Leinonen; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Negative Results in BioMedicine 2005, 4:5 http://www.jnrbm.com/content/4/1/5
Page 2 of 8
(page number not for citation purposes)
Background
Osteoclasts are bone-resorbing cells that are highly polar-
ized when physiologically active [1]. Their mononuclear
precursors are hematopoietic in origin, and remain non-
adherent in culture until they differentiate further from
the multipotent cell lineage [2,3]. Monocytes, macro-
phages and osteoclasts derive from the same precursor
cells [4]. Multinuclear osteoclasts are formed by fusion of
their committed mononuclear precursor cells and RANKL
is the major growth factor inducing osteoclast formation
[5]. Osteoclast morphology and activity is highly depend-
ent on the matrix that they are cultured on, bone being
their natural substrate. Mature osteoclasts undergo several
cycles of activation and inactivation, where bone is
resorbed in the active state and cells migrate in the resting
state. Eventually, the cells die apoptotically and, in vivo,
new bone formation by osteoblastic cells takes place to fill
the resorption lacuna.
Cell transfection is used in biomedical research to study
the role of individual gene products in vitro or in vivo. Viral
and non-viral gene transfer systems are available from sev-
eral suppliers, and several cell lines and primary cells can
efficiently be transfected [6,7]. Physiological barriers,
including the plasma membrane, still cause transfection
difficulties with distinct cell types. Cell-surface gly-
cosaminoglycans inhibit transfection in vitro [8], suggest-
ing that efficient gene transfer is as a sum of many
positively affecting parameters. Inside cells, DNA needs to
escape from the endosomes before their maturation into
lysosomes [9]. Cell-specific targeting of gene transfer par-
ticles would also be beneficial, and manipulating the gene
transfer complexes by adding targeting proteins or pep-
tides is currently under research [10].
When plasmid DNA is transfected to cells, it needs to be
transported to the nucleus to reach the transcription
machinery [11,12]. Nuclear transport may be achieved
either during mitosis when the nuclear membrane
becomes disrupted or by transport through the nuclear
pores. Transfection of non-dividing cells may be obtained
by activating nuclear uptake by inserting nuclear localiza-
tion signals into the transgene [13,14].
Adenoviral gene transfer into osteoclasts has been shown
to work well [15]. This is probably due to the numerous
αvβ3 integrin receptors that are located on the osteoclast
plasma membrane [16]. Reports describing non-viral
transfection on mature, adherent osteoclasts have not
been found. There are also reports describing transfection
of macrophages, like RAW264.7, that have after non-viral
gene transfer been induced to form multinuclear giant
cells [17]. It still remains controversial, however, whether
these cells are polykaryons or truly osteoclasts capable of
bone resorption. Due to a wish to study osteoclast migra-
tion and bone matrix removal in a more physiological
context, we cultured osteoclasts and their early mononu-
clear precursors on bone and used these cultures for trans-
fection. Earlier work in our laboratory suggested that
other conventional transfection methods like calcium
phosphate, DEAE-Dextran, electroporation, scrape-load-
ing and hypotonic shock cannot be used. In the current
paper we present data on the unsuccessful use of lipo-
somal systems in the transfection of mature human oste-
oclasts and their mononuclear precursors in vitro.
Results
Transfection reagent-DNA ratio
Transfection reagents have specific reagent-to-DNA ratios
that affect transfection efficiency and toxicity. In order to
determine which ratios to use in the following experi-
ments, we decided to test three ratios. On the basis of the
morphological analysis of the cells, one test ratio was cho-
sen for further analysis. Although disappointing at this
stage, a more detailed study was continued to determine
whether decreasing incubation time after transfection
would allow transgene expression.
Apoptosis index
Cell death is the major problem encountered when using
liposomal transfection systems. Therefore we counted the
number of apoptotic cells from Hoechst staining using a
conventional fluorescence microscope. Cultured osteo-
clasts were incubated with the transfection reagents for 2
h, followed by a 4 h, 8 h or 24 h culture period. In the
baseline control, where no transfection reagents or aden-
oviruses were added, only some apoptotic nuclei were
found and multinuclear osteoclasts remained polarized
and active, as determined by actin ring morphology (Fig-
ure 1, [18]) and resorption activity measurements (Figures
2 and 3). When samples treated with the transfection rea-
gents were evaluated, large numbers of apoptotic nuclei
were seen and only some nuclei remained unfractionated
(Figure 4). Intact osteoclasts could not be found in these
samples, and resorption activity was totally lost. The lack
of a dose-response suggests that even smaller amounts of
liposomes or PEI were not tolerable to the osteoclasts.
Some apoptotic nuclei were also seen in the adenovirus-
treated samples, but the majority of the nuclei remained
intact and many osteoclasts remained actively resorbing
bone.
Viability assay
In order to determine whether any combination of trans-
fection reagent concentration and incubation time would
allow cell survival, we cultured osteoclasts on 96 well
plates and measured dead and live cell fluorescence with
a microplate reader. As can be seen from Figure 5, we
could not avoid killing cells with the transfection rea-
gents. When the samples were monitored in more detailJournal of Negative Results in BioMedicine 2005, 4:5 http://www.jnrbm.com/content/4/1/5
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after cytochemical staining for the osteoclast marker
enzyme TRACP [19], it became evident that a total loss of
osteoclasts occurred already after a 1 h treatment with
transfection reagents. Adenoviral gene delivery also
resulted in osteoclast death and decreased viability, but
the majority of the cells remained alive and many cells
expressed the transgene.
We also wanted to check if it would be possible to trans-
fect the non-adherent CD34-positive mononuclear cells
and then induce osteoclast differentiation. The Live-Dead
assay was thus performed also with the mononuclear pre-
cursor cells. As can be seen from Figure 6, the viability
indexes remained somewhat higher but far too low as
compared to the baseline control or to the adenovirus-
treated samples.
Transfection efficiency
GFP expression was followed in adherent osteoclasts and
in non-adherent mononuclear precursors transfected for 4
hours and cultured in fresh medium for 1 h, 24 h, 48 h or
5 days. No GFP expression was noticed in osteoclasts after
transfection with any of the transfection systems tested
(Table 1). In comparison, adenoviral delivery of the
Visualization of actin rings and TRACP-positive cells in osteoclast cultures Figure 1
Visualization of actin rings and TRACP-positive cells in osteoclast cultures. Osteoclasts were differentiated in the 
presence of RANKL, M-CSF and TGF-β1 for 7 days, followed by fixation and staining of actin rings (a-c) and TRACP (d). Base-
line control is shown in a and d, and adenovirus-infected cells 4 h post infection are shown in b. A typical view of the cells incu-
bated 2 h with transfection reagents and 4 h in fresh medium is shown in c.Journal of Negative Results in BioMedicine 2005, 4:5 http://www.jnrbm.com/content/4/1/5
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transgene resulted in a 15% transfection efficiency of
multinuclear osteoclasts. When CD34-positive non-
adherent precursor cells were transfected, some cells were
positive 24 h and 48 h after transfection, but no positive
cells were seen on day 5 with any of the transfection rea-
gents tested (Table 2). In the adenovirus-infected cultures,
multiple GFP expressing cells was seen 24 h and 48 h after
infection and some cells also 5 days after infection. These
data suggest that transfection of the osteoclasts or the
mononuclear precursor cells was not feasible with the
conventional transfection methods.
Discussion
Osteoclasts are cells that need to be cultured as primary
cells or as a differentiation culture from bone marrow-
derived mononuclear precursor cells. The natural sub-
strate of osteoclasts is bone, and seeding the cells on a
non-natural substrate, like plastic or glass, has a major
effect on the regulation of gene expression and cell mor-
phology [18,20]. Therefore we aimed at transfecting
multinuclear osteoclasts adhered to bovine cortical bone,
a widely used system in osteoclast research. Adenoviral
transfection of osteoclasts was used in this study as the ref-
erence gene transfer system, while it has been shown to
work also with osteoclasts [15]. CAR-receptor bound ade-
noviruses are internalized via endocytosis after
attachment to αv integrins, which are widely distributed
on the osteoclast surface. Although viral gene delivery is at
it's best very efficient and rapid, a strong promoter may
drive excessive transgene production and interfere with
normal cell physiology. The use of human pathogens, like
adeno- and lentiviruses, also requires special attention
and authorization, while conventional transfection meth-
ods can be used in any laboratory.
Commercial modifications of liposomal gene delivery
systems and PEI-dependent endosomal disruption sys-
tems were systematically evaluated to determine whether
any of the concentration-incubation time combinations
would result in osteoclast transfection. To our disappoint-
ment, however, none of the 8 transfection systems could
provide satisfactory osteoclast transfection efficiency.
GFP-tagged actin was used as the transgene for easy mon-
itoring of gene transfer, but no transfected osteoclasts
were noticed. Adenoviral gene delivery was the only
method capable of providing sufficient transfection effi-
ciency. Among the non-adherent mononuclear precursor
cells, an equally poor transfection rate was obtained. The
most striking effect was the vast induction of apoptosis
Number of actin rings in osteoclast cultures Figure 2
Number of actin rings in osteoclast cultures. Cells 
were treated with transfection reagents for 2 h, followed by 
culture for 4 h, 8, or 24 h. Cells were stained with phalloidin 
and number of actin rings was counted to quantitate actively 
resorbing osteoclasts. BL, baseline with no additions; Ad, 
adenoviral infection of GFP; T1-T8, transfection reagents as 
shown in Tables 1 and 2. ANOVA: p < 0,001
Number of new resorption pits in osteoclast cultures Figure 3
Number of new resorption pits in osteoclast cultures. 
Bone slices were biotinylated before cells were treated with 
transfection reagents for 2 h, followed by culture for 4 h, 8, 
or 24 h. Biotinylated resorption pits were visualized with 
FITC-labelled streptavidin and all resorption pits were 
stained with TRITC-WGA lectin. Resorption occurring after 
transfection was determined as pits emitting only red fluores-
cence. BL, baseline with no additions; Ad, adenoviral infec-
tion of GFP; T1-T8, transfection reagents as shown in Tables 
1 and 2. The baseline control shown in the insert shows the 
staining pattern of the resorption pits before transfection 
(green) and overall resorption activity during the whole cul-
ture period (red). Yellow colour determines areas where 
both fluorochromes overlap. ANOVA: p < 0,001Journal of Negative Results in BioMedicine 2005, 4:5 http://www.jnrbm.com/content/4/1/5
Page 5 of 8
(page number not for citation purposes)
with both cationic liposomes and with PEI-dependent
endosomal proton sponges. When uptake of the
transfection reagent-packed DNA into the cells was mon-
itored in more detail, it could be noted that most of the
molecules never penetrated the plasma membrane. It was
recently shown that cell-surface glycosaminoglycans are
capable of inhibiting transfection [8]. The osteoclast
plasma membrane is coated with large amounts of
hyaluronic acid and other glycoproteins (for review see
[21]), and this may explain why the transfection reagents
are unable to deliver their cargo to the plasma membrane.
Another explanation for the lack of transfection may be
the low cell density. While commercial transfection rea-
gents are suggested to be used in sub-confluent to conflu-
ent cell cultures, our osteoclast cultures were appr. 50%
confluent (Figure 1d). Our cells were non-dividing, and
this may also contribute to the transfection difficulties.
Mature osteoclasts cannot be grown as suspension cul-
tures and confluency is difficult to control. However, oste-
oclasts take up plasma membrane-impermeable DNA-
and RNA molecules from culture medium [22-24]. For
antisense and siRNA-research, it would be optimal to
increase the uptake and intracellular availability of gene
knockdown-molecules in osteoclast cultures. While viral
gene transfer is difficult to control, the primary choice for
gene knockdown experiments would be a non-viral sys-
tem that allows transgene packaging, protection and suffi-
cient bioavailability.
Conclusion
Although many cell lines and some primary cells are easy
to transfect using calcium phosphate, DEAE-dextran,
electroporation, scrape loading or liposomal transfection
systems, these systems cannot be used on multinuclear
osteoclasts. These large, adherent, non-dividing cells are
fragile and undergo apoptosis rapidly when challenged
chemically or mechanically. Optimal cells for commercial
transfection systems should be in sub-confluent, rapidly
dividing growth phase, which cannot be provided in oste-
oclast cultures. Microinjection may be used for osteoclast
transfection, if only a few transfected osteoclasts are
enough and the expertise is available. For proper transfec-
tion of higher numbers of osteoclasts, however, the only
rational tools are the viral delivery systems.
Materials and methods
Cell culture
Human bone marrow-derived CD34-positive mononu-
clear cells were cultured on bovine cortical bone slices in
the presence of M-CSF (33 ng/ml, R&D Systems, UK) and
Apoptosis index in osteoclast cultures Figure 4
Apoptosis index in osteoclast cultures. Cells were 
treated with transfection reagents for 2 h, followed by cul-
ture for 4 h, 8, or 24 h. Nuclei were stained with Hoechst 
and apoptotic osteoclasts were counted with a fluorescence 
microscope. BL, baseline with no additions; Ad, adenoviral 
infection of GFP; T1-T8, transfection reagents as shown in 
Tables 1 and 2. ANOVA: p < 0,001
Viability index in osteoclast cultures Figure 5
Viability index in osteoclast cultures. Cells were 
treated with transfection reagents for 2 h, followed by cul-
ture for 4 h, 8, or 24 h. Osteoclast differentiation cultures 
were performed on collagen-coated plates to allow the use 
of the microplate reader. After transfection, cells were 
stained with Calcein AM and EthD and fluorescence of the 
dyes was measured using appropriate band pass filters. BL, 
baseline with no additions; Ad, adenoviral infection of GFP; 
T1-T8, transfection reagents as shown in Tables 1 and 2. 
ANOVA: p < 0,001Journal of Negative Results in BioMedicine 2005, 4:5 http://www.jnrbm.com/content/4/1/5
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RANKL (66 ng/ml, Peprotech, UK) as suggested by the
supplier (Cambrex, USA). TGF-β1 (1 ng/ml, R&D
Systems, UK) was added on day 3, and adherent,
terminally differentiated osteoclasts were transfected on
day 7. When non-adherent osteoclast precursors were
used, the transfections were performed on day 1. Cells
were cultured in high-glucose DMEM supplemented with
10% heat-inactivated fetal calf serum, 20 mM HEPES, 100
U/ml penicillin and 100 mg/ml streptomycin (all from
Gibco Invitrogen, UK). Cells were grown in 96 well plates
with 200 µl of medium for fluorescence measurements
with a plate reader. Bovine cortical bone slices were 150-
180 µm thick transversal sections that were sonicated and
sterilized by dipping in 70% ethanol before use. A control
group of cells attached to glass coverslips coated with type
I collagen (BD Biosciences, Belgium) was also included.
Non-attached cells were transfected in wells containing
type I collagen-coated glass coverslips or bone slices.
Transfection systems
The plasmid containing EGFP-actin (Clontech, USA) was
transfected to the cells to allow fluorescent visualization
of transfected actin filaments. For liposome-mediated
transfection, Metafectene (Biontex, USA), Lipofectamine
Plus (Gibco Invitrogen, UK), Tfx-50 (Promega Corp, USA)
and FuGene6, DOTAP and DOSPER (all from Roche, Ger-
many) were used according to the supplier's instructions.
Reagent/DNA ratios were as follows: 1 µg plasmid DNA
was complexed with 1.5, 3.0 or 6.0 µl of FuGene6 or Lipo-
fectamine Plus transfection reagent; or with 2.0, 3.0 or 4.0
µl of Tfx-50 or Metafectene transfection reagent; or with 5,
7.5 or 10 µg of DOTAP; or with 3, 7.5 or 12 µg of
DOSPER. Also the endosomal disruption-based transfec-
tion systems JetPei (PolyTransfection, USA) and DuoFect
(Quantum Appligene, USA) were used according to the
manufacturer's instructions. For DuoFect transfection, 50
µM deferrioxamine was added to the culture medium 24
h before transfection. With these systems, 1 µg plasmid
DNA was complexed with 0.5, 0.75 or 1.0 µl of DuoFect
transfection reagent or with 1.5, 3 or 4.5 µl of JetPei trans-
fection reagent.
To test the optimal transfection reagent-to-DNA ratio,
cells were incubated with transfection reagents for 2 h the
presence of serum, dipped in warm PBS and transferred
onto fresh culture plates containing medium and
osteoclast growth factors for an additional culture period
of 48 h. Cell morphology and transgene expression were
monitored microscopically and the following reagent-to-
DNA ratios were chosen to be used in the future experi-
ments: 1 µg plasmid DNA was complexed with 3.0 µl of
FuGene6, Lipofectamine Plus, Tfx-50 or Metafectene
transfection reagent; or with 7.5 µg of DOTAP or
DOSPER; or with 1.0 µl of DuoFect; or with 4.5 µl of JetPei
transfection reagent. In the following experiments, cells
were incubated with transfection reagents for 2 h in the
presence of serum, dipped in warm PBS and transferred
onto fresh culture plates containing medium and osteo-
clast growth factors for an additional culture period of 4
h, 8 h or 24 h. Transgene expression and cell viability were
evaluated with help of a fluorescence microscope (Leica)
and a microplate reader (Victor2, Wallac).
A commercial adenovirus resulting in the expression of
GFP under the CMV promoter was used as the transfection
control (QBiogene, USA). Cells were infected with 5000
virus particles of Ad5.CMV-GFP in 100 µl medium for 1 h,
after which 100 µl of fresh medium and osteoclast growth
factors were added. GFP expression and cell viability was
evaluated as already described.
Transfection efficiency and viability
Transgene expression in the cells was monitored under
fluorescence microscope 1 h, 24 h, 48 h and 5 days after
transfection, and all GFP-positive mononuclear cells and
osteoclasts (cells with at least 3 nuclei) were counted. For
counting apoptotic cells, 3% paraformaldehyde-2%
sucrose was used for fixing the cells prior to staining
nuclei with Hoechst as suggested by the supplier (Molec-
ular Probes, USA). Apoptotic nuclei were counted under
Viability index in CD34-positive mononuclear cell cultures Figure 6
Viability index in CD34-positive mononuclear cell 
cultures. Cells were treated with transfection reagents for 
2 h, followed by culture for 4 h, 8, or 24 h. CD34-positive 
cells were grown on collagen-coated plates and after trans-
fection, cells were stained with Calcein AM and EthD. Fluo-
rescence of the dyes was measured using the microplate 
reader and appropriate filter sets. BL, baseline with no addi-
tions; Ad, adenoviral infection of GFP; T1-T8, transfection 
reagents as shown in Tables 1 and 2. ANOVA: p < 0,001Journal of Negative Results in BioMedicine 2005, 4:5 http://www.jnrbm.com/content/4/1/5
Page 7 of 8
(page number not for citation purposes)
fluorescence microscope. To monitor cell viability in
detail, we stained dead and live cells with the Live/Dead-
system (Molecular Probes, USA). Cells grown on 96 well
plates were stained after transfection by adding 7 µM Cal-
cein AM (stained live cells) and 5 µM ethidium
homodimer-1 (EthD, detected dead cells) to the cell cul-
tures that were washed with warm PBS. Cells were incu-
bated with the dyes for 45 min in 100 µl PBS, followed by
fluorescence intensity measurements using exitation/
emission filter sets of 495/520 nm (Calcein AM) and 530/
642 nm (EthD). Viability indexes were counted by divid-
ing the live cell fluorescence by the dead cell fluorescence.
Morphological analysis
The effects of transfection reagents on the morphology of
cultured cells were monitored during culture with phase
optics, and more detailed morphological analysis was per-
formed on fixed samples. Cells were fixed in 3%PFA-2%
sucrose for 15 min. To monitor confluency and osteoclast
formation capacity in the cultures, cells were fixed and
stained for TRACP with the Leukocyte Acid Phosphatase
kit (Sigma, USA). Bone resorbing osteoclasts were deter-
mined by actin ring staining with AlexaFluor488 Phalloi-
din (Molecular Probes, USA). Resorption activity was
monitored in the samples by biotinylating the existing
resorption pits immediately before transfection with
sulfo-NHS-biotin (Pierce, USA) as described before [25].
After transfection and further culture, samples were fixed
and biotin was detected with FITC-streptavidin (DAKO,
Denmark) and all resorption pits were stained with
TRITC-WGA lectin (Sigma Aldrich, USA).
Statistical analysis
Data are expressed as mean ± SD of four replicas and all
experiments were independently performed twice (n = 8).
Differences from the control were examined for statistical
significance by analysis of variance and student's T-test. A
p-value less than 0,05 was considered significant.
Table 1: Transfection efficiency (% of live cells) in mature osteoclast cultures
1 h 24 h 48 h 5 d
Baseline 0 0 0,12 ± 0,042 0
Adenovirus 1,2 ± 0,095 9,7 ± 1,4 15,2 ± 3,4 3,8 ± 0,96
T 1 :  M e t a f e c t e n e 0000
T 2 :  L i p o f e c t a m i n e  p l u s 0000
T 3 :  T f x - 5 0 0000
T 4 :  F u G e n e 6 0000
T5: DOTAP 0000
T 6 :  D O S P E R 0000
T 7 :  J e t P e i 0000
T 8 :  D u o F e c t 0000
GFP-expressing and negative osteoclasts were counted using fluorescence microscopy and phase optics, and transfection efficiencies were counted. 
ANOVA: p = 1,4 × 10-8, n = 5.
Table 2: Transfection efficiency (% of live cells) in CD34-positive mononuclear cell cultures
1 h 24 h 48 h 5 d
Baseline 0 0,13 ± 0,031 0,47 ± 0,08 0
Adenovirus 2,7 ± 0,12 13,1 ± 1,4 22,6 ± 3,4 4,2 ± 0,96
T1: Metafectene 0 0,12 ± 0,042 0,23 ± 0,053 0
T2: Lipofectamine plus 0 0,24 ± 0,060 0,30 ± 0,11 0
T3: Tfx-50 0 0,10 ± 0,037 0,41 ± 0,091 0
T4: FuGene6 0 0,23 ± 0,071 0,22 ± 0,13 0
T5: DOTAP 0 0 0,56 ± 0,064 0
T6: DOSPER 0 0,16 ± 0,046 0,28 ± 0,13 0
T7: JetPei 0 0,20 ± 0,050 0,50 ± 0,15 0
T8: DuoFect 0 0 0,12 ± 0,056 0
GFP-expressing and negative osteoclasts were counted using fluorescence microscopy and phase optics, and transfection efficiencies were counted. 
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